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Colchicine is a relatively safe medication that is widely used for both prevention and
treatment of gout attack. However, serious adverse events, includingmyoneuropathy and
multiorgan failure, have been reported. We report a case of colchicine-induced
myoneuropathy in a female kidney transplant recipient who had been taking cyclos-
porine. She developed gastrointestinal discomfort and paresthesia 5 days after the
initiation of colchicine. She showed signs of myoneuropathy, and hepatic and renal
injury. Colchicine toxicity was suspected, and colchicine was discontinued. Her symp-
toms and laboratory ﬁndings improved gradually. Literature was reviewed for previous
reports of colchicine-induced myoneuropathy in solid organ transplant recipients.
& 2013. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Gout is common in organ transplant recipients as a conse-
quence of cyclosporine therapy, and impaired renal function acts
as another predisposing factor in renal transplant recipients [1].
As nonsteroidal anti-inﬂammatory drugs (NSAIDs) are potentially
nephrotoxic, colchicine is used frequently for both treatment and
prevention of acute gout attack. Although colchicine is a relatively
safe medication, it has been reported to be toxic. Gastrointestinal
symptoms are common symptoms of colchicine toxicity; however,
more severe adverse events such as myoneuropathy [2] and
multiorgan failure [3] have also been reported. Cyclosporine is
used widely as an immunosuppressant in organ transplant reci-
pients. A number of case reports of colchicine toxicity associated
with concomitant use of cyclosporine have been published [3–11],n Society of Nephrology. Publi
c-nd/4.0/).
logy, Samsung Medical
edicine, Seoul 135-710,
(W Huh).but they vary depending on the symptoms, dose, and duration of
medication; the affected organs; and outcomes. Here, we report
another case of myoneuropathy and multiple organ involvement
associated with concomitant use of colchicine and cyclosporine in
a renal transplant recipient, and review the previous case reports.Case report
A 57-year-old female, with diabetes, hypertension, and a
history of kidney transplantation 13 years ago from a deceased
donor, was admitted due to epigastric pain and poor oral intake.
She maintained normal renal function for 10 years, but her
estimated glomerular ﬁltration rate started to ﬂuctuate 3 years
prior to admission. Her serum creatinine was stabilized at
1.65 mg/dL about 2 years ago and was maintained in the range
of 1.4–1.6 mg/dL thereafter. The patient developed the ﬁrst acute
gout attack on her left ankle 2 years ago, and was started on
prednisolone 10mg twice a day and allopurinol 100mg once a
day. After 1 month, prednisolone was tapered off gradually,
but the aggravation of gout about 2 months prior to admissionshed by Elsevier. This is an open access article under the CC BY-NC-ND
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glycemia, prednisolone was substituted by colchicine 0.3 mg twice
a day about 3 weeks prior to admission. The patient had been
taking deﬂazacort 3 mg once a day, cyclosporine 50mg twice a
day, and mycophenolate 500mg twice a day. She was also taking
rosuvastatin 20 mg once a day, which had been used since January
2009 without any side effects. Five days after starting colchicine,
she developed epigastric pain with nausea and vomiting. She
began to complain of tingling sensation and numbness on the
plantar area of both feet and the radial side of both hands 2 days
later. After 21 days on colchicine, she visited the emergency
department of our center. On initial presentation, physical exam-
ination revealed no abnormal ﬁnding, except mild dehydration.
Sensory function of affected limbs was normal, and she did not
show any signs of motor weakness. The complete blood count
showed white blood cell count of 8,770/μL, hemoglobin level
of 15.8 g/dL, and platelet count of 198,000/μL. Chemistry proﬁles
were as follows: total bilirubin 1.5 mg/dL, aspartate transaminase
166 U/L, alanine transaminase 118 U/L, alkaline phosphatase
77 U/L, blood urea nitrogen 26.4 mg/dL, creatinine 1.97 mg/dL,
uric acid 7.6 mg/dL, creatine kinase 1,497 IU/L, lactate dehydro-
genase 973 IU/L, and myoglobin 2,150.8 ng/mL (Table 1). Serum
concentration of cyclosporine was 66.3 ng/mL, which was within
the therapeutic range. Her previous laboratory tests, performed
3 weeks earlier, showed normal serum transaminase levels and
serum creatinine of 1.00 mg/dL. Serology for viral hepatitis was
negative. A presumptive diagnosis of colchicine toxicity was
made based on medication history and myoneuropathy with
liver and kidney involvement. Colchicine and rosuvastatin were
stopped immediately, and the patient was admitted. Levels of
serum creatinine, creatine kinase, and lactate dehydrogenase
began to fall on the day after admission. Epigastric discomfort
and nausea began to improve on hospital Day 2. Serum transa-
minases also started to decline on the same day. Her tingling
sensation and numbness had been on the slow improve and
remained until discharge 8 days later. Two weeks after discharge,
her paresthesia remained on both feet, but was improving
gradually. The levels of serum transaminases, creatinine, and
muscle enzymes returned to normal. Rosuvastatin was restarted,
but her symptoms and laboratory abnormalities did not recur
thereafter. Prednisolone 5 mg was prescribed to be used in an
“as-needed” basis for acute exacerbation of gout. She had
reported two acute attacks since October 2011, which responded
well to prednisolone. Since then, she had no acute attack and her
serum uric acid has remained at an optimal level.Table 1. Laboratory ﬁndings of the patient
Serum concentration
–20 0 1 2
CK (IU/L) 1,497 1,239 2,316
LD (IU/L) 973 761
AST (U/L) 23 166 168 227
ALT (U/L) 28 118 115 153
BUN (mg/dL) 30.8 26.4 23.8 16.7
Creatinine (mg/dL) 1 1.97 1.71 1.42
ANC (10*/μL) 4.67 4.569 1.7
Cyclosporine (ng/mL) 63.5 66.3
n Day –20 denotes the day colchicine was prescribed. On Day 0, the patient v
patient was discharged on Day 8. On Day 22, the patient visited the outpat
ALT, alanine transaminase; ANC, absolute neutrophil count; AST, aspartate t
dehydrogenase.Discussion
Previous case reports of colchicine myoneuropathy in patients
with concomitant administration of cyclosporine were searched
on MEDLINE, using the phrase “colchicine AND cyclosporine AND
toxicity.” Among 48 results, case reports were selected, whose
demographic and clinical characteristics are summarized in
Table 2.
In 10 out of 13 cases, patients were male, which is in
accordance with the male-to-female incidence ratio of gout.
Mean age of the affected patients was 56.9710.0 years. Doses
of colchicine were 1 mg/d or lower in most of the cases,
but doses higher than 1 mg/d were administered in three
cases. Development of colchicine toxicity after its chronic use
was reported in one case, after 8 years [7]. However, serum
concentration of cyclosporine was also found to be at a toxic
level in this case, so possibility of cyclosporine toxicity cannot
be ruled out. Excluding this extreme, the mean duration of
colchicine use was 12.679.7 days. Side effects have been
reported after 2 days or 3 days of colchicine administration
[4,6,10]. Serum colchicine concentration was measured only in
one case, which was within the therapeutic range. Serum
concentrations of cyclosporine were above 400 ng/mL in three
cases, and above 1,000 ng/mL in two of them. High serum
cyclosporine level in these patients raises suspicion of cyclos-
porine toxicity, but it might be secondary to acute kidney
injury due to colchicine toxicity. Signs of myopathy and
hepatic involvement were universal in reported cases. Serum
creatinine was above the normal range in all cases in which
creatinine level was reported, but the degree of kidney injury
was difﬁcult to estimate due to a lack of data on baseline
serum creatinine level. Neutrophil count was below the
normal range in two cases, which was also seen in our patient.
All patients recovered after cessation of colchicine. Laboratory
abnormalities were usually normalized within 2 weeks, but
complete recovery from weakness and paresthesia took longer
than a month in most of the cases reviewed.
Colchicine binds to tubulin in a poorly reversible manner
[12], preventing its polymerization, which is required for the
formation of a microtubule. Microtubules are involved in cell
division, signal transduction, regulation of gene expression,
and migration of cell. Concomitant administration of cyclos-
porine increases the risk of colchicine toxicity. It is suggested
that this might be due to strong inhibition of the membrane P
glycoprotein by cyclosporine [8,13]. A drug–drug interactionDay*
3 4 5 6 7 22
1,177 499 87
711 629 492
176 124 67 54 44 23
162 149 106 91 75 25
12.5 14.6 18.7 14.7 14.3 16.1
1.27 1.09 0.98 0.99 0.83 1
1.71 1.58 1 1.64 2.41 5.25
56.8
isited the emergency department and colchicine was discontinued. The
ient clinic.
ransaminase; BUN, blood urea nitrogen; CK, creatine kinase; LD, lactate
Table 2. Clinical characteristics of 13 previous case reports
No Refs Sex Age
(y)
Transplanted
organ(s)
Colchicine dose
(mg/d)
Duration
of
colchicine
use
Serum
concentration
(colchicine;
ng/mL)
Cyclosporine
dose
(mg/d)
Serum
concentration
(cyclosporine;
ng/mL)
Symptoms CK
(IU/L)
LD
(IU/L)
Myoglobin
(ng/mL)
BUN
(ng/mL)
Cr
(mg/dL)
AST
(IU/L)
ALT
(IU/L)
Neutrophil
(cells/mm3)
1 [6] M 49 Kidney 2.4 3 d 250 267 Pain, weakness 14,958 1,102 ≥300 2.7 561 403
2 [4] M 70 Kidney 1 16 d Weakness 425
3 [4] M 55 Kidney 1 2 d Pain 1,840
4 [4] F 49 Kidney 1 26 d Pain 1,234
5 [4] M 56 Kidney 1 11 d Pain 251
6 [4] M 67 Kidney 1 10 d Pain, weakness 1,135
7 [7] M 53 Heart 8 y 350 1,450 Weakness, pain, fatigue ≥3,000 36 2.9
8 [7] M 56 Heart 0.6 450 ≥2,000 Weakness, fatigue 449 43 1.9
9 [7] F 57 Heart 0.6 120 Weakness 700
10 [9] M 72 Kidney 1 30 d 150 134 Pain, weakness 766 1,102 1.2 170
11 [3] 62 Kidney 2 for 3 d,
1 mg qod
for 5 d, then
1 for 9 d
17 d 250 Constipation, nausea,
abdominal pain, fatigue,
confusion, arrhythmia
2,671 898 2.27 341 321 1,300
12 [10] M 60 Heart 1 3 d 7 350 475 Fever, dyspnea, tachycardia,
arrhythmia
1,553 2,188 23.1 7.9 2,061 3,074 700
13 [11] M 34 Heart, lung 1 mg tid for 1 d,
1 mg bid for
1 d, then 1 for
6 d
8 d 13 340 111 Cough, dyspnea, diarrhea,
general weakness
3,206 573 52.7 2.44 122 136
ALT, alanine transaminase; AST, aspartate transaminase; bid, twice daily; BUN, blood urea nitrogen; CK, creatine kinase; Cr, creatinine; LD, lactate dehydrogenase; q.o.d, four times daily; tid, three
times daily.
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Huh et al / Colchicine-induced myoneuropathy 77study performed in vivo revealed that cyclosporine increases
total exposure, half-life, and peak concentration of colchicines
signiﬁcantly [14].
Regarding diagnosis, temporal relations and distinctive syn-
drome of muscle injury and symptoms suggesting peripheral
neuropathy should raise suspicion of colchicine toxicity. No
speciﬁc test provides a deﬁnitive diagnosis, but muscle biopsy
and electromyography/nerve conduction studies were performed
frequently in previous cases. The characteristic histological fea-
tures of colchicine myopathy are vacuolar myopathy—the pre-
sence of lysosomes and autophagic vacuoles [2,6,9]. Absence of
inﬂammatory ﬁnding is useful to exclude polymyositis.
Electromyography and nerve conduction studies may also
demonstrate distinctive features. Myopathic motor unit poten-
tials and early recruitment in proximal limb and truncal
muscles, positive sharp waves, or complex repetitive dis-
charges are seen. Reduced amplitude of motor and sensory
responses, but normal or borderline-slow conduction veloci-
ties, which suggests mild axonal neuropathy, can be seen in
nerve conduction studies [9].
It is questionable whether muscle biopsy or electrodiag-
nostic studies are always necessary for the diagnosis. They are
often helpful in ruling out other diseases of polymyositis and
Guillain–Barré syndrome, respectively. However, polymyositis
usually takes an insidious course over several months, and
antinuclear antibodies are detected in up to 80% of patients
with dermatomyositis or polymyositis. Guillain–Barré syn-
drome does not cause prominent muscle injury as observed
in cases of colchicine toxicity. Therefore, those invasive tests
can be reserved for atypical presentation or delayed recovery
after cessation of colchicine.
The mainstay of treatment is a prompt cessation of colchi-
cine and supportive care. Colchicine is not removed by dialysis
[15], and there is no proven treatment to reduce the serum
concentration of colchicine. Thus, currently, the highly qualiﬁed
intensive care with organ support is the only option in severe
cases. Artiﬁcial liver or organ transplantation could be
theoretically possible options, but have never been practiced in
this condition.
Treatment of gout is complicated in those patients who
have experienced colchicine toxicity. Corticosteroid and
NSAIDs remain as alternative options for the management of
acute exacerbation. A short course of oral corticosteroid is a
safe and effective treatment option, especially considering
nephrotoxicity of NSAIDs. Control of hyperuricemia and avoid-
ance of risk behaviors cannot be overemphasized, as colchicine
cannot be taken for the prevention of acute gout attack.
Colchicine can cause severe myoneuropathy with multi-
organ involvement, and its risk is increased in patients with
concomitant use of cyclosporine. Withdrawal of colchicine
usually results in rapid clinical improvement, but associated
mortality has also been reported. Thus, clinical suspicion and
prompt cessation of colchicine are very important. In addition,
invasive and costly diagnostic tests can be avoided by a timelydiagnosis. Therefore, all physicians who are involved in the
care of renal transplant recipients should be familiar with
colchicine-induced myoneuropathy.Conﬂict of interest
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